Real-world experience of elbasvir/grazoprevir in Taiwan: This study was focused on liver and renal adverse effects

被引:1
作者
Hsieh, Yi-Chung [1 ]
Lin, Chih-Lang [2 ]
Hung, Chao-Hung [3 ,4 ]
Chen, Chien-Hung [4 ,5 ]
Tung, Shui-Yi [3 ,4 ]
Lin, Chun-Yen [1 ,4 ]
Hu, Tsung-Hui [4 ,5 ]
Lu, Sheng-Nan [3 ,4 ]
Chien, Rong-Nan [2 ,4 ]
Sheen, I-Shyan [1 ,4 ]
机构
[1] Linkou Chang Gung Mem Hosp, Div Hepatogastroenterol, Taoyuan, Taiwan
[2] Keelung Chang Gung Mem Hosp, Div Hepatogastroenterol, Keelung, Taiwan
[3] Chiayi Chang Gung Mem Hosp, Div Hepatogastroenterol, Chiayi, Taiwan
[4] Chang Gung Univ, Coll Med, Taoyuan, Taiwan
[5] Kaohsiung Chang Gung Mem Hosp, Div Hepatogastroenterol, Kaohsiung, Taiwan
关键词
adverse effect; elbasvir; grazoprevir; hepatitis C; real-world experience; HEPATITIS-C VIRUS; GENOTYPE; INFECTION; GRAZOPREVIR MK-5172; ELBASVIR MK-8742; TREATMENT-NAIVE; EFFICACY; SAFETY; COMBINATION; RIBAVIRIN; THERAPY;
D O I
10.1111/jvh.13262
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Elbasvir/grazoprevir with or without ribavirin has excellent efficacy and safety for the treatment of hepatitis C virus (HCV) genotype 1 and 4 patients. The real-world experience has been reported but the detailed analysis of liver and renal adverse effects is lacking. This study evaluated the real-world experience relating to the effectiveness and liver/renal safety of elbasvir/grazoprevir in HCV genotype 1 patients with compensated liver disease. In the four medical centres of Chang Gung Medical System, 350 HCV genotype 1 patients with compensated liver disease who were treated with elbasvir/grazoprevir were enrolled. Clinical characteristics and laboratory data were collected. The effectiveness (sustained virologic response 12 weeks after end of treatment, SVR12) and safety were assessed. A consecutive series of 350 patients with a mean age of 68.8 +/- 10.0 years old were enrolled. The majority were treatment-naive (72.3%), genotype 1b (97.7%) and advanced fibrosis/cirrhosis (94.3%). Seventy-nine (22.6%) had hepatocellular carcinoma and 23 (6.6%) had coinfection with hepatitis B. The effectiveness of SVR12 was 94.6% (95% CI: 92.2%-97.0%) in the full analysis set and 99.1% (95% CI: 98.1%-100.1%) in the per-protocol set. There were two relapses and one nonresponder. Seven (2.0%) patients had adverse events resulting in premature discontinuation of treatment. Five of them were considered drug-related. One was due to autoimmune hepatitis. Contrary to previous reports, around 49% of ALT elevation was observed after 8 weeks, and in two patients was due to hepatitis B flares. As to the renal function during the course of therapy, a minor deterioration of eGFR was observed in patients with baseline eGFR >= 60 mL/min/1.73 m(2), but not in those with baseline eGFR <60, <60-30 or <30 mL/min/1.73 m(2). In this real-world data, elbasvir/grazoprevir was effective with few liver/renal adverse effects. One patient developed autoimmune hepatitis.
引用
收藏
页码:505 / 513
页数:9
相关论文
共 33 条
[1]   Grazoprevir plus elbasvir in HCV genotype-1 or-4 infected patients with stage 4/5 severe chronic kidney disease is safe and effective [J].
Alric, Laurent ;
Ollivier-Hourmand, Isabelle ;
Berard, Emilie ;
Hillaire, Sophie ;
Guillaume, Maeva ;
Vallet-Pichard, Anais ;
Bernard-Chabert, Brigitte ;
Loustaud-Ratti, Veronique ;
Bourliere, Marc ;
de Ledinghen, Victor ;
Fouchard-Hubert, Isabelle ;
Canva, Valerie ;
Minello, Anne ;
Nguyen-Khac, Eric ;
Leroy, Vincent ;
Saadoun, David ;
Trias, Dominique ;
Pol, Stanislas ;
Kamar, Nassim .
KIDNEY INTERNATIONAL, 2018, 94 (01) :206-213
[2]  
[Anonymous], 2018, Recommendations for testing, managing, and treating hepatitis C
[3]  
[Anonymous], ZEP ELB GRAZ TABL
[4]   Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma [J].
Beste, Lauren A. ;
Green, Pamela K. ;
Berry, Kristin ;
Kogut, Matthew J. ;
Allison, Stephen K. ;
Ioannou, George N. .
JOURNAL OF HEPATOLOGY, 2017, 67 (01) :32-39
[5]   Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study [J].
Blach, Sarah ;
Zeuzem, Stefan ;
Manns, Michael ;
Altraif, Ibrahim ;
Duberg, Ann-Sofi ;
Muljono, David H. ;
Waked, Imam ;
Alavian, Seyed M. ;
Lee, Mei-Hsuan ;
Negro, Francesco ;
Abaalkhail, Faisal ;
Abdou, Ahmed ;
Abdulla, Maheeba ;
Abou Rached, Antoine ;
Aho, Inka ;
Akarca, Ulus ;
Al Ghazzawi, Imad ;
Al Kaabi, Saad ;
Al Lawati, Faryal ;
Al Namaani, Khalid ;
Al Serkal, Youssif ;
Al-Busafi, Said A. ;
Al-Dabal, Layla ;
Aleman, Soo ;
Alghamdi, Abdullah S. ;
Aljumah, Abdulrahman A. ;
Al-Romaihi, Hamad E. ;
Andersson, Monique I. ;
Arendt, Vic ;
Arkkila, Perttu ;
Assiri, Abdullah M. ;
Baatarkhuu, Oidov ;
Bane, Abate ;
Ben-Ari, Ziv ;
Bergin, Colm ;
Bessone, Fernando ;
Bihl, Florian ;
Bizri, Abdul R. ;
Blachier, Martin ;
Blasco, Antonio J. ;
Mello, Carlos E. Brandao ;
Bruggmann, Philip ;
Brunton, Cheryl R. ;
Calinas, Filipe ;
Chan, Henry L. Y. ;
Chaudhry, Asad ;
Cheinquer, Hugo ;
Chen, Chien-Jen ;
Chien, Rong-Nan ;
Choi, Moon Seok .
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (03) :161-176
[6]   Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE [J].
Buti, Maria ;
Gordon, Stuart C. ;
Zuckerman, Eli ;
Lawitz, Eric ;
Calleja, Jose L. ;
Hofer, Harald ;
Gilbert, Christopher ;
Palcza, John ;
Howe, Anita Y. M. ;
DiNubile, Mark J. ;
Robertson, Michael N. ;
Wahl, Janice ;
Barr, Eliav ;
Forns, Xavier .
CLINICAL INFECTIOUS DISEASES, 2016, 62 (01) :32-36
[7]   Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection [J].
Chung, Raymond T. ;
Ghany, Marc G. ;
Kim, Arthur Y. ;
Marks, Kristen M. ;
Naggie, Susanna ;
Vargas, Hugo E. ;
Aronsohn, Andrew I. ;
Bhattacharya, Debika ;
Broder, Tina ;
Falade-Nwulia, O. ;
Fontana, Robert J. ;
Gordon, Stuart C. ;
Heller, Theo ;
Holmberg, Scott D. ;
Jhaveri, Ravi ;
Jonas, Maureen M. ;
Kiser, Jennifer J. ;
Linas, Benjamin P. ;
Lo Re, Vincent, III ;
Morgan, Timothy R. ;
Nahass, Ronald G. ;
Peters, Marion G. ;
Reddy, K. Rajender ;
Reynolds, Andrew ;
Scott, John D. ;
Searson, Gloria ;
Swan, Tracy ;
Terrault, Norah A. ;
Trooskin, Stacey B. ;
Wong, John B. ;
Workowski, Kimberly A. .
CLINICAL INFECTIOUS DISEASES, 2018, 67 (10) :1477-1492
[8]   Autoimmune Hepatitis During Ledipasvir/Sofosbuvir Treatment of Hepatitis C: A Case Report [J].
Covini, Giovanni ;
Bredi, Elena ;
Badalamenti, Salvatore ;
Roncalli, Massimo ;
Aghemo, Alessio ;
Colombo, Massimo .
HEPATOLOGY COMMUNICATIONS, 2018, 2 (10) :1179-1183
[9]   Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy A Randomized Trial [J].
Dore, Gregory J. ;
Altice, Frederick ;
Litwin, Alain H. ;
Dalgard, Olav ;
Gane, Edward J. ;
Shibolet, Oren ;
Luetkemeyer, Anne ;
Nahass, Ronald ;
Peng, Cheng-Yuan ;
Conway, Brian ;
Grebely, Jason ;
Howe, Anita Y. M. ;
Gendrano, Isaias N. ;
Chen, Erluo ;
Huang, Hsueh-Cheng ;
Dutko, Frank J. ;
Nickle, David C. ;
Bach-Yen Nguyen ;
Wahl, Janice ;
Barr, Eliav ;
Robertson, Michael N. ;
Platt, Heather L. .
ANNALS OF INTERNAL MEDICINE, 2016, 165 (09) :625-+
[10]   EASL Recommendations on Treatment of Hepatitis C 2018 [J].
Pawlotsky J.-M. ;
Negro F. ;
Aghemo A. ;
Berenguer M. ;
Dalgard O. ;
Dusheiko G. ;
Marra F. ;
Puoti M. ;
Wedemeyer H. .
JOURNAL OF HEPATOLOGY, 2018, 69 (02) :461-511